HOME >> MEDICINE >> NEWS
Grant expands Indiana University-Kenya AIDS program

The success of a two-year program to treat HIV/AIDS in adults and children in Kenya has attracted a one-year, $1.6 million grant from the U.S. Agency for International Development. The announcement was made today by Sen. Richard Lugar (R-Ind.), chairman of the Senate Foreign Relations Committee.

The program, Academic Model for the Prevention and Treatment for HIV/AIDS (AMPATH), was created by the Indiana University School of Medicine, the Moi Teaching and Referral Hospital, and the Moi University Faculty of Health Sciences in Kenya.

The new grant will allow IU and Moi physicians to increase the number of HIV-infected people they treat in Kenya from 2,000 to 15,000, and to establish HIV treatment and prevention programs in two additional rural communities over the next five years.

AMPATH is a model program that attracted the U.S. AID funding after successfully enrolling and treating more than 1,500 patients using modern HIV/AIDS therapy. It also instituted a successful mother-to-child-transmission prevention program in which more than 90 traditional birth attendants have been trained to care for HIV-infected women using prevention interventions. The program has educated community support groups about HIV, the importance of prevention and the need for testing.

Faculty and students also have established a practical, low-cost, high-production 10-acre farm in Kenya to provide high quality macro-nutrition to HIV-infected families.

AMPATH is opening a new facility in May 2004 in urban Kenya for teaching, research and patient care. A second new building will be opened in the rural community of Mosoriot for treatment, counseling, teaching and research. These and other treatment facilities will feature an electronic medical record system to help physicians track patients and provide better care.

In addition to the increase in patients treated and the two new rural programs, the new U.S. AID funding will:


    '"/>


Contact: Pamela Su Perry
pperry@iupui.edu
317-274-7722
Indiana University
5-Feb-2004


Page: 1 2

Related medicine news :

1. Grant to study why teens smoke
2. Grants from Research to Prevent Blindness to support eye researchers surpassed $8 million in 2003
3. GlaxoSmithKline Drug Discovery and Development Research Grant Program 2003
4. More than $34 Million in SPORE Grants
5. Grant funds Indian River lagoon research
6. GlaxoSmithKline Drug Discovery and Development Research Grant Program 2003
7. Program wins first Youth Development Award from Grant Foundation
8. Grant of 20 million to establish the Schistosomiasis Control Initiative
9. Grant will advance research of infection-fighting blood cells
10. UK Researchers Receive $1.14 Million NIH Grant To Study A Molecule That May Have A Role In Diseases Involving Oxidative Cell Death
11. UK Researchers Receive Grants To Examine Benefits Of Aerobic Exercise For People With Spinal Cord Injuries

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Grant expands Indiana University Kenya AIDS program

(Date:5/21/2013)... An attack on glioblastoma brain tumor cells that ... an early study to establish the proper dose level, ... developed at Duke and tested in an ongoing phase ... have an abundance of receptors that work like magnets ... cells. , The investigational therapy, known as PVSRIPO, ...
(Date:5/21/2013)... Adeptia, a leading provider of innovative cloud ... is the featured company in an impact report written ... “Adeptia Bets on Converged Cloud Integration and Process-Orchestration Suites,” ... products, pricing, customers and competition. , “For ... integration and process orchestration, especially when price, ease of ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... some of the changes brought about by the disorder ... New research has found that people with diabetes who ... risk of having a severe low blood sugar (hypoglycemia) ... people with diabetes who aren,t depressed. "Depression ...
(Date:5/21/2013)... Grapefruits have long been known for their ... how medical therapies like anti-cancer drugs are delivered ... researchers have uncovered how to create nanoparticles using ... how to use them as drug delivery vehicles. ... Ph.D., and their team today (May 21, 2013), ...
(Date:5/21/2013)... May 21, 2013 Benefit Express Services, ... medium, and small organizations, will be hosting a free ... team from Findley Davies. The presentation will focus on ... in compliance with new Health Care Reform Requirements. The ... employees. , “Benefit Express regularly hosts free educational ...
Breaking Medicine News(10 mins):Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:Adeptia Featured in Recent 451 Research Impact Report 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Benefit Express to Host Workplace Wellness Webinar 2
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)... 2013  BioRestorative Therapies, Inc. ("BRT" or the "Company") ... developing stem cell based therapies for various personal applications, ... President and CEO, will be presenting at the Marcum ... held on Thursday, May 30, 2013 at the Grand ... New York City.  Mr. Weinreb,s presentation will take place ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
Cached News: